The Influence of Liposomal Encapsulation on Sodium Cromoglycate Pharmacokinetics in Man

University of Wales College of Cardiff
Pharmaceutical Research (Impact Factor: 3.95). 06/1989; 6(7):633-636. DOI: 10.1023/A:1015917918130

ABSTRACT The pharmacokinetics of pulmonary-administered sodium cromoglycate (SCG) has been studied in five healthy volunteers. SCG, 20 mg, was inhaled as a solution and encapsulated in dipalmitoyl phosphatidylcholine/cholesterol (1:1) liposomes. Liposomal SCG produced detectable drug levels in plasma from four volunteers taken 24 and 25 hr after inhalation. Inhaled SCG solution, although producing peak plasma levels more than sevenfold greater than liposomal drug, was not detectable in 24-hr samples from any volunteer. The decline in plasma levels following inhalation of liposomal SCG (reflecting the absorption phase) was best described by a biexponential equation. The two absorption rate constants differed by more than an order of magnitude. The rapid absorption phase was probably due to free or surface-adsorbed SCG in the liposomal formulation, since the absorption rate constant for this phase did not differ significantly from the absorption rate constant for SCG in solution. The phase of slow drug absorption may then be attributed to absorption of drug released from vesicles. The data indicate that encapsulation of SCG prior to pulmonary administration prolonged drug retention within the lungs and altered its pharmacokinetics.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Nebulisers are widely used to generate therapeutic aerosols for inhalation therapy. In this paper the factors determining aerosol size and drug output from ultrasonic nebulisers are discussed. The mechanism of droplet formation is described in relation to capillary wave production on the surface of the liquid being atomised and the implosion of cavitation bubbles near its surface. There are many commercially available ultrasonic nebulisers, and their design is a major factor determining aerosol characteristics and output, in particular the operating frequency of the devices (usually 1–3 MHz), the presence of a fan to assist droplet output and the positioning of baffles. The size of aerosols produced and the rate of fluid output is often larger than comparable jet nebulisers. They also have less tendency to increase the concentration of dissolved solutes. However, the residual or `dead' volume of fluid is usually larger. The physicochemical properties of fluids for nebulisation significantly affect nebuliser performance. Viscosity is particularly important, with an increased viscosity increasing aerosol size but reducing output. Fluids of high viscosity cannot be efficiently atomised. Although most preparations for nebulisation are solutions, some suspension formulations are also commercially available. Suspensions are generally less efficiently delivered by ultrasonic than jet nebulisers with an inverse relationship between the size of suspended particles and their output. During use, the temperature of fluids in the reservoir of ultrasonic nebulisers increases. This may result in the degradation of heat sensitive materials. However, potentially heat sensitive such as proteins and liposomes have been successfully delivered using such devices.
    International Journal of Pharmaceutics 07/1997; 153(1). DOI:10.1016/S0378-5173(97)00105-1 · 3.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Liposomes are spherical lipid carrier vesicles that vary in size (typically in the range of 20 nm to 20 μm), and are composed of single or multi-concentric bilayers, and have the ability to entrap both hydrophilic therapeutic agents within their central aqueous core or lipophilic drugs within their bilayer compartment. These carriers can transport drugs to particular sites of action within the pulmonary system by employing specially designed delivery devices. These devices work through specific mechanisms and their performance depends upon the formulation. Dry powder inhalers deliver dry powdered formulations. By contrast, pressurized metered dose inhalers deliver liquid formulations when an appropriate liquefied propellant is included. However, nebulizers are capable of delivering aqueous suspensions or solutions with no need for inclusion of a propellant. Liposomes were first reported in 1965 and since then significant developments in liposome research have emerged. Liposomes are now well established as carrier systems that accommodate therapeutic agents and deliver them to various sites in the body. Liposomes can sustain the release of the entrapped therapeutic materials, hence enhancing the therapeutic outcome. Liposome carrier systems have been studied extensively for prophylaxis against and the treatment of pulmonary diseases
    Biomaterials and Medical Tribology, Edited by J. Paulo Davim, 01/2014: chapter Liposome-based carrier systems and devices used for pulmonary drug delivery: pages 395-443; Woodhead Publishing., ISBN: 978-0-85709-220-5
  • Source